Global Biotech Weekly

This week, we will focus on the critical near-term catalysts anticipated in summer 2025, particularly emphasizing those expected to materialize in the immediate term.InflaRx N.V. (NASDAQ:IFRX) is a Germany-based biopharmaceutical company focused on developing monoclonal antibodies that target activation products of the complement system, aiming to treat life-threatening inflammatory diseases. Its lead asset, IFX-1, is an intravenously administered anti-C5a monocThe ongoing Phase 2a basket trial of INF904, which began dosing in December 2024, is evaluating safety, pharmacokinetics, and potential signs of clinical benefit in 75 patients - 45 with chronic spontaneous urticaria (CSU) and 30 with HS. This open-label, multi-center trial consists of a 28-day treaLisata Therapeutics (NASDAQ:LSTA) is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases. The company’s lead program, certepetide (LSTA1), is being investigated in the Phase 2a BOLSTER trial for the treatment of intrThe BOLSTER trial is a double-blind, placebo-controlled, randomized Phase 2a study being conducted at multiple centers in the U.S. It includes two cohorts: patients with previously untreated CCA and those who have progressed following first-line therapy. Following accelerated enrollment, the first-lNuvalent (NASDAQ:NUVL) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing small molecule kinase inhibitors for patients with genetically defined cancers. Founded in 2019, the company has built a pipeline targeting key oncogenic drivers, incThe ARROS-1 study is a pivotal, registrational-intent, dose escalation and expansion trial assessing the safety, tolerability, and efficacy of zidesamtinib. The trial includes both TKI-naïve and TKI-pretreated patients across five expansion cohorts, with Phase 1 focused on determining the recommende